Pathogen Inactivation for Blood Products, Protein Therapeutics and Vaccines – CFI
For the physical inactivation of enveloped and non-enveloped viruses with no residual contamination and negligible denaturation of proteins and enzymes
CFI Mechanisms of Inactivation
CFI has the ability to physically disrupt and inactivate pathogen particles, explaining its ability to inactivate non-enveloped viruses such as Polio, and a variety of tough microorganisms such as yeast and other Gram-positive microorganisms.
CFI also inactivates enveloped viruses, such as HIV and influenza, by a partial phospholipid solubilization/liberation mechanism.
CFI of enveloped viruses such as MuLV, VSV, TGE, BVD, Sindbis and HIV, and non-enveloped viruses such as Hepatitis A, Polio, Adeno, Reo, EMC and Parvovirus B19 has been demonstrated.
In summary, CFI:
CFI can inactivate a broad range of enveloped and non-enveloped viruses, more than 6 logs (1 million particles per milliliter) in less than 20 seconds for some viruses. Increasing the number of stages, like a distillation column, increases inactivation levels. Volumetric throughput is increased by increasing cross-sectional area.